Modulation of specific active immunization against murine melanoma using recombinant cytokines

Surgical Oncology

Volumn 5, Issue 5-6, 1996, Pages 221-229

  Stidham, K R ^a   Ricci, W M ^a   Vervaert, C ^a   Abdel Wahab, Z ^a   Seigler, H F ^a   Darrow, T L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Interleukin 1 ; Interleukin 2; Murine; Specific active immunization; Tumour immunity

Indexed keywords

CYTOKINE; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030432498     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0960-7404(96)80025-9     Document Type: Article

References (34)

1. HF Seigler WW Shingleton RS Metzgar Non-specific and specific immunotherapy in patients with melanoma Surgery 72 1972 162 174
2. J Avent C Vervaert HF Seigler Non-specific and specific active immunotherapy in a B16 murine melanoma system J Surg Oncol 12 1979 87 96
3. MS Mitchell J Kan-Mitchell RA Kempf W Harel H Shau S Lind Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant Cancer Res 48 1985 5883 5893
4. BD Kahan NR Pellis SJ LeGrue T Tanaka Immuno-therapeutic effects of tumour-specific transplantation antigens released by 1-butanol Cancer 49 1982 1168 1173
5. SJ LeGrue JP Allison CM Macek NR Pellis BD Kahan Immunobiological properties of 1-butanol-extracted cell surface antigens Cancer Res 41 1981 3956 3960
6. FJ Robb A Munck KA Smith T-cell growth factor receptors. Quantitation, specificity and biological relevance J Exp Med 154 1981 1455 1462
7. S Gillis Interleukin 2: Biology and biochemistry J Clin Immunol 3 1993 1 3
8. KA Smith LB Lachman JJ Oppenheim MF Favata The functional relationship of the interleukins J Exp Med 151 1980 1551 1556
9. EL Larsson NN Iscove A Coutinho Two distinct factors are required for induction of T-cell growth Nature 283 1980 664 666
10. KA Smith S Gillis PE Baker D McKenzie T-cell growth factor mediated T-cell proliferation Ann N Y Acad Sci 332 1979 423 432
11. SA Rosenberg JJ Mule PJ Spiess CM Reichert SL Schwarz Regression of established pulmonary metastases and subcutaneous tumour mediated by the systemic administration of high-dose recombinant interleukin 2 J Exp Med 161 1985 1169 1188
12. JJ Mule JC Yang SS Afreniere SA Rosenberg Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2 J Immunol 139 1987 285 294
13. DN Mannel SB Mizel J Diamantstein W Falk Induction of interleukin 2 responsiveness in thymocytes by synergistic action of interleukin 1 and interleukin 2 J Immunol 134 1985 3108 3110
14. S Nakamura K Nakata S Kashimoto H Yoshida M Yamada Aptitumour effect of recombinant human interleukin 1 alpha against murine syngeneic tumours Jpn J Cancer Res 77 1986 767 773
15. F Bellardelli E Proietti V Ciolli Interleukin-1/β induces tumour necrosis and early morphologic and metabolic changes in transplantable mouse tumours. Similarities with the antitumour effects of tumour necrosis factor a or b Int J Cancer 44 1989 116 120
16. H Huges M Campos S van Drunen Littel-van den Hurk Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV Vaccine 10 1992 226 230
17. A Weinberg T Merigan Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines J Immunol 140 1988 294 299
18. V Schijns I Ciaassen A Vermeulen M Horzinek A Osterhaus Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosis factor-*, interleukin-1*, interleukin-2 and interferon--/ on the immunogenicity of an inactivated rabies vaccine J Gen Virol 75 1994 55 63
19. K McCullough L Pullen D Parkinson The immune response against foot-and-mouth disease virus: Influence of the T-lymphocte growth factors IL-1 and IL-2 on the murine humoral response in vivo Immunol Lett 31 1991 41 46
20. M Good D Pombo M Lunde Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2 J Immunol 141 1988 972 977
21. Y Barnavon H Iwaki J Bash Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2 J Surg Res 45 1988 523 530
22. P Arroyo P Bash M Wallack Active specific immunotherapy with vaccinia colon oncolystate enhances the immunomodulatory and antitumour effects of inteleukin-2 and Interferon-α in a murine hepatic metastasis model Can Immunol Immunother 31 1990 305 311
23. J McLaughlin J Schlom J Kantor J Greiner Improved immunotherapy of a recombinant carcino-embryonic antigen vaccinia vaccine when given in combination with interleukin-2 Cancer Res 56 1996 2361 2367
24. K Naito NR Pellis BD Kahan Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumour-specific transplantation antigen and cyclophosphamide Cancer Res 48 1988 101 108
25. WM Ricci T Darrow C Vervaert Z Wahab HF Seigler Interleukin-2 augments the host response to tumour cells in a murine model of specific active immunotherapy Surg Forum XLII 1991 475 477
26. CS McCune DM Marzuis Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumour model Cancer Res 50 1990 1212 1215
27. D Berd HC Maguire MJ Mastrangelo Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide Cancer Res 46 1986 2572 2577
28. D Boraschi L Villa G Volpini Differential activity of interleukin 1-alpha and interleukin 1-beta in the stimulation of the immune response in vivo Eur J Immunol 20 1990 317 321
29. KM Pezzella ME Neville JJ Huang In vivo inhibition of tumour growth of B16 melanoma by recombinant interleukin-1β. I. Tumour inhibition parallels lymphocyte-activating factor activity of interleukin-1β proteins Cytokine 2 1990 357 362
30. ME Neville KM Pezzella K Schmidt W Galbraith N Ackerman In vivo inhibition of tumour growth of B16 melanoma by recombinant interleukin 1β. II. Mechanism of inhibition: the role of polymorphonuclear leukocytes Cytokine 2 1990 3456 3463
31. G Forni T Musso C Jemma D Boraschi A Tagliabue M Giiovarelli Lymphokine-activated tumour inhibition in mice. Ability of a nonapeptide of the human IL-1β to recruit anti-tumour reactivity in recipient mice Cancer Res 142 1989 712 718
32. A Porgador E Tzehoval E Vadai M Feldman L Eisenbach Immunotherapy via gene therapy: comparison of the effects of tumour cells transduced with the interleukin-2, interleukin-6, or interferon-γ genes J Immunother 14 1993 191 201
33. B Gansbacher R Bannerji B Daniels K Zier K Cronin E Gilboa Retroviral vector-mediated y-interferon gene transfer into tumour cells generates potent and long lasting antitumour immunity Cancer Res 50 1990 7820 7825
34. A Porgador R Bannerji Y Watanabe M Feldman L Eisenbach Antimetastatic vaccination of tumour-bearing mice with two types of IFN-γ gene-inserted tumour cells J Immunol 150 1993 1458 1470